CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate
Benzinga Newsdesk 13 hours ago
NewsEarningsEarnings BeatsEarnings Misses
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 1.71 percent increase over losses of $(1.17) per share
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 1.71 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $12.669 million which beat the analyst consensus estimate of $10.495 million by 20.72 percent. This is a 1.33K percent increase over sales of $889.000 thousand the same period last year.